Bruker, Premier Biosoft Enter Reselling Agreement for SimLipid, SimMet Software | GenomeWeb

NEW YORK(GenomeWeb) – Premier Biosoft and Bruker said today that they have entered a reselling agreement under which Bruker will co-market and resell Premier's SimLipid and SimMet informatics software. 

SimLipid and SimMet are intended for mass spec-based analysis of, respectively, lipids and metabolites and facilitate automated LC-MS and MS/MS data processing workflows and identification and quantitation of these analytes, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.